论文部分内容阅读
目的:探讨β-微管蛋白Ⅲ(β-tubulinⅢ),Bcl-2在非小细胞肺癌(NSCLC)组织中的表达及临床意义。方法:采用免疫组化SP法检测两种耐药因子在61例NSCLC中的表达。结果:β-tubulinⅢ,Bcl-2在NSCLC组织中表达阳性率分别为73.8%,52.5%,β-tubulinⅢ,Bcl-2在NSCLC阳性表达率大于正常肺组织(P<0.05);β-tubulinⅢ表达阳性率在中-低分化期大于高分化期(P<0.05),Bcl-2表达阳性率在高分化期大于中-低分化期(P<0.05);β-tubulinⅢ阳性表达率晚期大于早期(P<0.05),Bcl-2表达阳性率早期大于晚期(P<0.05);β-tubulinⅢ,Bcl-2在NSCLC中的表达有相关性(P<0.05)。在30例接受紫杉类为基础的化疗的NSCLC中,化疗有效率在β-tubulinⅢ,Bcl-2低表达组和β-tubulinⅢ,Bcl-2高表达组分别为77.8%,61.1%和19.1%,16.7%(即分别为4.1倍和3.7倍),差别有统计学意义(P<0.05)。结论:β-tubulinⅢ,Bcl-2高表达,提示对紫杉类药物耐药;β-tubulinⅢ,Bcl-2是NSCLC的预后因素且其表达与预后相关,可能成为新型的临床预后指标。联合检测非小细胞肺癌组织中耐药因子的表达有益于化疗方案的选择、化疗疗效及预后的判断。
Objective: To investigate the expression and clinical significance of β-tubulinⅢ and Bcl-2 in non-small cell lung cancer (NSCLC). Methods: Immunohistochemical SP method was used to detect the expression of two drug resistance factors in 61 cases of NSCLC. Results: The positive rates of β-tubulin Ⅲ and Bcl-2 in NSCLC were 73.8% and 52.5%, respectively. The positive rates of β-tubulin Ⅲ and Bcl-2 in NSCLC were higher than those in normal lung tissues (P <0.05) The positive rate of Bcl-2 was higher than that of moderately-poorly differentiated (P <0.05) in the middle-low differentiation stage (P <0.05) P <0.05). The positive rate of Bcl-2 expression was higher in the early stage than that in the late stage (P <0.05). The expression of β-tubulinⅢ and Bcl-2 in NSCLC was correlated (P <0.05). In 30 NSCLC patients receiving chemotherapy based on taxane, the effective rate of chemotherapy was 77.8%, 61.1% and 19.1% in the low expression of β-tubulinⅢ, Bcl-2 low expression group and β-tubulinⅢ, Bcl-2 high expression group respectively , 16.7% (ie 4.1 times and 3.7 times respectively), the difference was statistically significant (P <0.05). CONCLUSION: The high expression of β-tubulinⅢ and Bcl-2, which indicates that they are resistant to taxanes. Β-tubulinⅢ and Bcl-2 are prognostic factors of NSCLC, and the expression ofβ-tubulinⅢ and Bcl-2 may be related to the prognosis. It may be a new clinical prognostic indicator. Joint detection of non-small cell lung cancer tissue resistance factor expression is conducive to the choice of chemotherapy, chemotherapy efficacy and prognosis.